Why C. difficile Infection is Treated with Oral Vancomycin
Oral vancomycin is the preferred treatment for C. difficile infection (CDI) because it achieves superior cure rates compared to other antibiotics, particularly in severe disease, and concentrates directly in the colonic lumen where C. difficile resides. 1, 2
Mechanism of Action and Pharmacokinetics
The key advantage of oral vancomycin lies in its unique pharmacokinetic profile. When taken orally, vancomycin is poorly absorbed systemically—less than 1% enters the bloodstream—allowing it to remain concentrated in the gastrointestinal tract where it directly targets C. difficile. 3 This results in fecal concentrations exceeding 100 mg/kg, far above the levels needed to kill the bacteria. 3
In contrast, intravenous vancomycin has no effect on CDI because it is not excreted into the colon. 1 This is why the route of administration is critical—oral delivery is essential for efficacy.
Evidence Supporting Superiority Over Metronidazole
Multiple high-quality guidelines consistently demonstrate vancomycin's superiority:
For Severe CDI
In severe CDI, vancomycin achieves significantly higher cure rates than metronidazole (97% vs 76% in intention-to-treat analysis). 4 The 2019 WSES guidelines found that metronidazole had lower clinical cure rates for severe CDI (OR = 0.46,95% CI 0.26–0.80; p = 0.006). 1
For All CDI Severities
The 2018 IDSA/SHEA guidelines now recommend vancomycin 125 mg four times daily for 10 days as first-line therapy for all initial CDI episodes, regardless of severity (strong recommendation, high quality evidence). 2 This represents a shift from older guidelines that reserved vancomycin for severe cases only.
The 2019 WSES guidelines note that moderate quality evidence from a Cochrane review suggests vancomycin is superior to metronidazole in all cases of CDI. 1
Dosing Considerations
The standard dose is 125 mg four times daily for 10 days. 4, 2 Higher doses (500 mg four times daily) are sometimes used in fulminant disease with hypotension, shock, ileus, or megacolon, though evidence for this practice is limited. 1
Research shows no significant benefit to high-dose regimens for non-fulminant CDI—low dose (125 mg) achieves equivalent outcomes to high dose (250-500 mg) with no difference in recurrence rates. 5, 6
Alternative Routes for Special Situations
When oral administration is impossible due to ileus or inability to swallow:
- Vancomycin retention enema (500 mg in 100-500 mL saline every 6 hours) can be administered rectally 1
- Intravenous metronidazole (500 mg every 8 hours) should be added as adjunctive therapy in fulminant cases with ileus 2
- Trans-stoma vancomycin may be effective in surgical patients with Hartmann resection, ileostomy, or colon diversion 1
Recurrent CDI Management
For first recurrence, tapered and pulsed vancomycin regimens are preferred over standard 10-day courses (e.g., 125 mg four times daily for 10-14 days, then twice daily for 7 days, once daily for 7 days, then every 2-3 days for 2-8 weeks). 2 This approach reduces subsequent recurrences compared to standard dosing.
Fidaxomicin (200 mg twice daily for 10 days) is an alternative that shows lower recurrence rates than vancomycin, though it is non-inferior for initial cure. 4, 1
Safety Profile
Oral vancomycin does not increase the risk of vancomycin-resistant Enterococcus (VRE) compared to metronidazole when used for CDI treatment. 7 This addresses a longstanding concern about widespread vancomycin use. However, one study found increased VRE carriage at 8 weeks post-treatment (50% vs 24%, p=0.048), though clinical VRE infections were not increased. 8
Common pitfalls to avoid:
- Do not use IV vancomycin alone for CDI—it will not work 1
- Do not extend metronidazole courses beyond 10-14 days due to cumulative neurotoxicity risk 1
- Monitor renal function in elderly patients (>65 years) as they have increased nephrotoxicity risk 3
- Do not discontinue treatment prematurely in elderly patients who may take longer to respond 3